Life Sciences & Biotechnology
Title : | A phase II B open label randomised controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID-19 infection (ICE study) |
Area of research : | COVID-19 Research, Life Sciences & Biotechnology |
Focus area : | COVID-19 Therapeutics |
Principal Investigator : | Dr Biju George, Professor, Christian Medical College (CMC), Vellore |
Timeline Start Year : | 2020 |
Contact info : | biju@cmcvellore.ac.in |
Details
Executive Summary : | The study aims to understand if the use of Ivermectin is associated with a more rapid clearance of the virus compared to standard supportive treatment and whether this rapid reduction will lead to better outcomes. |
Outcome/Output: | Patients with COVID-19 infection were randomised to receive either standard of care (SOC0], single dose of 12 mg or 24 mg of Ivermectin. Serial naso-pharyngeal swabs for RT-PCR were sent on days 3, 5 and 7. All patients were followed up till hospital discharge or death. There was no difference in the RT-PCR negativity rates on days 5 and 7 or a > 2 log reduction in RTPCR between the three groups. Clinical resolution of infection and mortality were similar between the three groups. |
Organizations involved